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Background: It has been suggested that the formation of osteoblasts in bone marrow is closely associated with
adipogenesis, and the balance between osteogenesis and adipogenesis differentiation of MSCs (mesenchymal stem
cells) is disrupted in osteoporosis. In order to improve the treatment of osteoporosis, available agents with roles of
regulating the balance is highly desirable. Emodin is a natural anthraquinone derivative extracted from Chinese
herbs, which have been used to treat bone diseases for thousands of years. However, the underlying molecular
mechanisms of emodin in modulating osteogenesis and adipogenesis remain poorly understood.
Methods: The molecular mechanisms of emodin on the processes of osteogenesis and adipogenesis in
ovariectomized mouse and BMSCs (bone marrow mesenchymal stem cells) have been studied. We have analyzed
the effects of emodin in vivo and in vitro. Female ICR mice were assigned to three groups: sham group,
ovariectomy group, emodin group. Efficacy was evaluated by H&E, immunohistochemical assay and Micro-CT. In
vitro, we analyze the effect of emodin—at concentrations between 0.1 μM and 10 μM-on the processes of inducing
osteogenesis and inhibiting adipogenesis in BMSCs by ALP, Oil red O staining, real time RT-PCR and western blot.
Results: As our experiment shows that emodin could increase the number of osteoblast, BMD (bone mineral
density), BV/TV (trabecular bone volume fraction), Tb.N (trabecular number) and Conn.D (connectivity density) of
OVX (ovariectomized) mice and decrease the bone marrow fat tissue and adipocytes. The genes and proteins
expression of osteogenesis markers, such as Runx2, osterix, collagen type I, osteocalcin, or ALP were up-regulated.
While, the genes and proteins involved in adipogenesis, PPARγ, C/EBPα and ap2 were down-regulated.
Conclusion: It proves that emodin inhibits adipocyte differentiation and enhances osteoblast differentiation from
BMSCs.
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The decrease in osteoblastogenesis associated with an
increasing bone marrow adipogenesis which accompan-
ies osteoporosis in aging populations have long been
reported [1,2]. Since osteoblasts and adipocytes are de-
rived from a common multipotential MSC progenitor, it
has been proposed that the balance between osteogen-
esis and adipogenesis differentiation of mesenchymal
stem cells (MSCs) is disrupted in osteoporosis [3]. The
consequence of these changes is a progressive marrow
adiposity that accompanies osteoporosis in the aging* Correspondence: yangfengdudu@163.com
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reproduction in any medium, provided the orprocess. Several agents, including drugs, oxidative stress,
nutrients, hormones, and metabolic signals, can switch
multipotent MSC differentiation toward adipocyte or
osteoblast formation [4]. Regulator in the balance be-
tween osteogenesis and adipogenesis of MSCs may be a
novel therapeutic target.
Emodin, (1, 3, 8-trihydroxy-6-methylan-thraquinone,
molecular structure is Figure 1) a natural anthraquinone
derivative found in the roots and rhizomes of numerous
plants such as Polygonum multiflorum, rhubarb, Alose.
has been demonstrated to possess multiple biological
activities and abilities to ameliorate metabolic disorders
[5]. In addition, hydroxyanthraquinones such as emodin,
are phytoestrogens with an affinity to human estro-
gen receptors [6]. Polygonum multiflorum which actived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Figure 1 (See legend on next page.)
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osis in traditional Chinese medicine for a long time.
Pharmacological studies have demonstrated that emodin
exhibits anti-cancer, anti-inflammatory, anti-fibrosis ef-
fects [7-9]. The research on anti-bone loss and anti-
adipogenesis is a few. Lee SU et al. reported that emodin
could activate the mRNA expression of bone morphogeneticprotein (BMP)-2 in the mouse osteoblast [10]. Emodin has
effect on the inhibition of mouse 3 T3-L1cell’s proliferation
and differentiation [11]. Yang’s data suggest emodin could
inhibit the proliferation and differentiation of preadipo
-cytes in a dose and time dependent manner, and induce
apoptosis of preadipocytes in a certain degree [12]. This kind
of studies showed that the emodin promoted osteoblastic
(See figure on previous page.)
Figure 1 The structure of emodin. (A) Molecular formula: C15H10O5, molecular weight: 270.23. HE Staining showed more osteoblasts attaching
to the surface of bone trabeculae of emodin-OVX group (C) and SHAM group (B) than OVX group (D). Osteoblast activity scores from HE staining
slices: N.ob/T.Ar (osteoblast number per trabecular area). (E) and N.ob/B.PM (osteoblast number per bone perimeter) (F) rose up in OVX + emodin
group. The columns represent the mean ± SE of three independent experiments. *: P < 0.05 vs. OVX. Immunohistochemical assessments of the protein
of Runx2 (G, H, I) and PPARγ (J, K, L). Immunohistochemical analysis showed more increase in Runx2 protein distribution in the OVX + emodin groups
than OVX group. Immunohistochemical analysis showed more increase in PPARγprotein distribution in the OVX + emodin groups. Representative 3-D
images of lumbar vertebral body of sham-operated mice (M:SHAM), ovariectomy mice (N:OVX) and emodin-treated OVX mice (O:OVX + emodin) by
micro-CT. Bone loss and trabecular bone deterioration are evident in the OVX group and the progression of bone loss and bone deterioration is partially
rescued by emodin treatment.
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limitation of previous studies is that they did not evaluate
the effect of emodin at the tissue level and on BMSC differ-
entiation. Therefore, the effect of emodin on the balance of
osteogenesis and adipogenesis has been investigated both
in vitro and in vivo. A novel therapeutic target of emodin
for osteoporosis have been found.
Methods
Animal grouping and treatments
Thirty 6-month-old ICR female mice were purchased
from Shanghai Laboratory animal center (SCXK2007-
0005). The study was conducted in the Institute of
Orthopedics, Shaanxi University of Traditional Chinese
Medicine. The animal handlings and experimental pro-
cedures were approved by the Committee on the Ethics
of Animal Experiments of Shaanxi University of Trad-
itional Chinese Medicine, which conforms to the Guide
for the Care and Use of Laboratory Animals published
by the US National Institutes of Health.
The mice were divided into three groups: (1) Sham-
ovariectomized group (sham), (2) ovariectomized group
(OVX), (3) ovariectomized group treated with emodin
(OVX + E). Mice were anesthetized with ketamine and
were positioned dorsal side up. Aseptically, each fallo-
pian tube was located bilaterally and both ovaries were
removed. The transection sites were ligated. Each sur-
gical procedure is same, the mice in OVX + E group
were intraperitoneal injected with emodin at dose of
100 mg/(kg · d) twice every three days for three months
after the OVX surgery.
Histomorphology evaluation
Lumbar vertebra was prepared for the bone histomor-
phology analysis. Decalficied frontal sections of lumbar
vertebra were embedded in paraffin wax and cut (6 μm
thickness) using a microtome (Leica EG1160, Germany).
The histological section was stained by haematoxylin &
eosin (H&E). Sections were examined by using a photo-
microscope set (Olympus DP71; Olympus, Tokyo), and
morphometric study was performed by using an image
processing and analysis software (Mediacybernetics, USA).
Moreover, Bone marrow was taken from the anterior
iliac crest with needle. Plastic embedding of undecalcifiedcores was used. Sections 3 μm in thickness were stained
with Gill’s hematoxilin. From each specimen, 8 to 10 ran-
dom microphotographs were obtained for the Image Pro
Plus 6.0 software analysis. In each specimen, the following
morphometric parameters were determined: (1) percent of
marrow fat tissue fraction; (2) number of adipocytes/mm3.
Immunohistochemical staining for Runx2 and PPARγ
Immunohistochemical staining was performed in 6 μm-thick
paraffin sections mounted on positive-charged slides. Sections
were deparaffinized with xylene and rehydrated through de-
scending concentrations of ethanol. Antigen retrieval was per-
formed by heating the slides in Target Retrieval Solution,
pH 9.0 (Dako Denmark, Glostrup, Denmark) at 97°C in a
water quench for 5 min for the interstitial and cell surface
antibodies or with boiling citrate buffer, pH 6.0 for 20 min in
a microwave oven for nuclear markers.
The following primary antibodies were applied over-
night at 4°C: rabbit polyclonal anti- Runx2 (1:50 dilution;
Abcam), and rabbit polyclonal anti-PPARγ (1:50 dilution;
Abcam). Biotinylated secondary antibody (anti-rabbit,
BioGenex) was applied for 20 min at 37°C, and then the
slides were exposed to a streptavidin-biotin, alkaline phos-
phatase complex. Negative controls were performed by
omitting the primary antibody. The color reaction was
elicited by using 3, 3′-diaminobenzidine (DAB) solution
(invitrogen, USA), visualized, and examined by using a
photomicroscope set (Olympus DP71).
Bone microarchitecture assessment by microcomputed
tomography
Bone microarchitecture in lumbar vertebra was assessed
using microcomputed tomography (μCT) (MicroCT80,
SCANCO Medical, Switzerland). Trabecular bone of the
lumbar vertebra was scanned so that 250 images were
acquired. All scans were performed in a 1,024 × 1,024
matrix resulting in an isotropic voxel resolution of 16 μm
in all three spatial dimensions. An integration time of
150 ms per projection was used.
The scanning procedure and reconstruction of 3-D
images were performed. Trabecular parameters included
trabecular bone volume fraction (BV/TV, percent),
number (Tb.N, number per millimeter), thickness (Tb.Th,
micrometer), and separation (Tb.Sp, micrometer).
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BMSCs were obtain from the bone marrow of the bilat-
eral tibia and femur of eight mice per group. The cells
were thawed and seeded in α-minimum essential
medium (α-MEM, Gibco, invitrogen, USA), 10% fetal
bovine serum (FBS, Gibco, invitrogen, USA), Grown
and confluent cells were trypsinized, collected, and
plated at 500 cells per square centimeter in 100 mm plates
(Corning incorporated, USA). When the cells came closer
to confluence, the differentiation was initiated by means of
specific media. The osteoblast media (OM) also contained
10−8 M dexamethasone, 10 mM β-glycerophosphate, and
0.05 mM L-ascorbic acid, while the adipocyte media
(AM) contained 10−6 M dexamethasone, 0.5 mM iso-
butylmethylxanthine, 100 μM indomethacin and insulin
10 mg/L. Treatment with emodin (purity >80%; molecu-
lar weight: 270.23; purchased from You-si Biotech Co.
Shanghai, China) started at the same time as the differen-
tiation process. The toxicity of these concentrations of
emodin on the MSCs was tested by MTT assay. Logarith-
mic phase cells were collected and seeded in 96-wells
plate at a density of 1000-10000/well at 37°C, After the
cells attached, different concentration of emodin were
added to the medium and incubated 16-48 hours. MTT
(5 mg/ml) was dissolved in PBS. 20 μl of MTT solution
was added to each well and incubate at 37°C for 4 hours.
The medium was removed with syringe. 150 μl of DMSO
was added to each well and pipette up and down to dis-
solve crytals. The plate was measured absorbance at wave-
length at 570 nm.
Real time PCR
Total RNA was obtained from cells in culture using
Trizol Reagent (Invitrogen, USA), according to the
manufacturer’s instructions, and cDNA was synthe-
sized from total RNA (iScript™ cDNA Synthesis Kit, Bio-
Rad), which had been previously treated with DNAse I
(Sigma-Aldrich) following the manufacturer’s instructions.
Real-time polymerase chain reaction (RT-PCR) to quantify
the mRNA of osteoblastic and adipocytic markers was
performed in the Rotor-Gene 3000 (Corbett Research,
Australia) using SYBR® Green as a double-strand DNA-
specific binding dye. PCR reactions were carried out in a
final volume of 20 μl, with 1 μl of cDNA sample, 1 μl of
each primer (Table 1), and Quantitect® SYBR® Green mas-
ter mix (TaKaRa BIO). The conditions for the Rotor-Gene
3000 were 95°C for 15 min, 40 cycles of 95°C for 30 s, 60°C
for15 s, and 72°C for 30 s. The relative expression of
mRNA was calculated according to the 2-ΔΔCt method.
The endogenous control is β-actin.
ALP staining
To confirm osteogenesis, cells cultured in osteogenic
media (OM) were stained using 1-step NBT/BCIP(Thermo scientific). The cells were fixed in 4% paraformal-
dehyde for 10 min, washed with dH2O, mixed the 1-step
NBT/BCIP until desired stain developed.
Oil red O staining
To confirm adipogenesis, cells cultured in adipogenic
media (AM) were stained using oil red O (Sigma). The
cells were fixed in 4% paraformaldehyde for 10 min,
washed with dH2O, and incubated with an oil red O so-
lution for 20 min at room temperature (RT). Then the
cells were rinsed with dH2O, counterstained with Gill’s
Hematoxylin II (Sigma-Aldrich), and viewed under a
light microscope.
Western blot analysis
To examine the effect of emodin on Runx2 and PPARγ
protein, primary BMSCs were seeded in 6-well plates at
a density of 5 × 106 cells/well. Culture cells were treated
with emodin for 21 days. Cells lysates were extracted
with RIPA protein extraction reagents (Beyotime) ac-
cording to the manufacturer’s protocol. Proteins were
transblotted onto a PVDF membrane (BIO-RAD) and
the membrane was blocked with 5% milk in PBST for
1 hour at room temperature (RT). The samples were in-
cubated with the primary antibody overnight at 4°C and
the HRP-conjugated secondary antibodies (Abcam) for
1 hour. The polyclonal rabbit Runx2 antibody and the
polyclonal rabbit PPARγ antibody were obtained from
Abcam. After the immunocomplex was removed by
stripping buffer (Chemicon Int.), the same membrane
was reblotted with mouse anti-β-Actin antibody (Sigma)
for the loading control. Then visualized with Odyssey in-
frared imaging system (Li-COR inc.) according to the
manufacturer’s instructions.
Statistical analysis
All the assays were made twice. The data are expressed
as the average with its SE. The statistical analysis was
carried out using the SPSS 17.0 software. The results ob-
tained from these two independent experiments were
compared using the one-way ANOVA followed Tukey’s




It revealed that cancellous bone was formed of a dense
network of bone trabeculae in the SHAM group and os-
teocytes appeared in their lacunae (Figure 1B). The end-
osteal surface of trabeculae was lined by osteoprogenitor
cells, osteoblasts and osteoclasts in Howship’s lacunae.
Bone marrow spaces were seen between the trabeculae.
The results in the OVX-mice revealed the cancellous
bone trabeculae lost their normal architecture and
Table 2 Effect of emodin on fat tissue and adipocytes in
bone marrow
Group Fat tissue fraction (%) Number of adipocytes/mm3
Sham 18.40 ± 1.51 2040.05 ± 358.65
OVX 41.39 ± 2.60 4219.18 ± 432.30
Emodin 22.52 ± 3.48* 2627.08 ± 467.09*
Data are presented as mean ± SEM *significantly different from the
OVX group:P < 0.05.
Table 1 Mouse primers for real-time quantitative PCR assays
Genes Forward primer Reverse primer
β-actin 5′-CTTAGTTGCGTTACACCCTTTCTTG-3′ 5′-CTGCTGTCACCTTCACCGTT CC-3′
ALP 5′-CATGAAATACGAGATCCACCGAGAC-3′ 5′-ATGCGACCACC CTC CACGAAG-3′
Runx2 5′-CATGGTGGAGATCATCGC-3′ 5′-ACT CTT GCC TCG TCC ACT C-3′
Osterix 5′-GCA GCTAGAAGGGCGTGGTG-3′ 5′-GCAGGCAGGTGAACTTCTTC-3′
OC 5′-GAGGGCAGCGAGGTAGTGAAG-3′ 5′-GATGTGGTCAGCCAACTCGTCA-3′
ColI 5′-TCCGACCTCTCTCCTCTGAA-3′ 5′-GAGTGG GGTTATGGAGGGAT-3′
BMP4 5′-TGAGCCTTTCCAGCAAGTTT-3′ 5′-CTTCCCCGTCTCAGGTATCA-3′
PPARγ 5′-CCAGAAAGCGATTCCTTCAC-3′ 5′- CACGTTAGTTTCACCTCGGA-3′
C/EBPα 5′-AAGAAGTCGGTGGACAAGAACAG-3′ 5′-TGCGCACCGCGATGT-3′
ap2 5′-GGCCAGGAATTTGACGAAGTC-3′ 5′-AGCGTAACTTGAGATGTTGTAAGACA-3′
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row spaces widened (Figure 1C). Osteoclasts were appar-
ently increased as compared with the sham group.
Erosion cavities were detected in the endosteal surface
in some trabeculae and proliferation of osteoblasts was
also detected in some areas.
The emodin-OVX mice showed marked improvement
as compared to the OVX-mice. The cancellous bone tra-
beculae partially regained near normal structure and the
trabecular bone widened, its broken points lessened and
its Howship’s lacunae shallowed as compared to the
SHAM- operated control group (Figure 1D).
Meanwhile, quantitation showed that the number of oste-
oblasts was increased at unit tissue area and unit bone per-
imeter in the OVX and emodin-OVX group (P < 0.05), the
osteoblast number in sham group was non-significant dif-
ferent from that in the emodin- OVX group (Figure 1E, F).
To evaluate the effect on bone marrow fat tissue and adi-
pocytes, the values of two parameters (fat tissue fraction
and number of adipocytes/mm3) were significantly higher
in OVX as compared with sham and emodin (Table 2).
The difference between the emodin and OVX group was
significant. The data indicates emodin can decrease the
bone marrow fat tissue and adipocytes of OVX mice.
Immunohistochemical staining for Runx2 and PPARγ
Immunohistochemical study of the section in the OVX-
mice revealed strong immunoreactivity for PPARγ, while
much weaker immunostaining for Runx2. However, the
density of the Runx2 positive staining of the Emodin-
OVX group increased dramatically compared with the
OVX group (Figure 1G, H, I). And immunohistochemi-
cal staining for PPARγ was weaker after emodin treat-
ment (Figure 1J, K, L).
Bone microarchitecture assessment by microcomputed
tomography
There was a significant difference in trabecular parame-
ters between the OVX group and emodin-OVX group(Table 3). 3-D images showed deterioration of trabecular
bone morphology in the ovariectomized mice. Bone tra-
becular appeared discontinuous and lessen. while these
progression of bone loss and deterioration is partially res-
cued by emodin in emodin-OVX mice (Figure 1L, M, N).
Emodin enhanced BMSC proliferation
Structure of emodin was shown in Figure 1A. The effect
of emodin on cell proliferation of BMSC has been tested
by MTT assay. As shown in Figure 2A, emodin has
significant effects on cell growth at the concentrations
of 0.1 μM-10 μM after 3-d treatment, and emodin show in-
hibition on cell proliferation at 2d. However, when the dose
reached 100 μM, Emodin started to show toxic effect.
Based on these observations, 0.1 μM, 1 μM and 10 μM of
emodin were used in the following experiments.
Emodin up-regulates mRNA and protein expression of
osteogenesis markers
Changes in gene expression, as well as in the osteoblast
phenotype, were observed when emodin was present in
the OM. The expression of BMP4 genes induced by OM
with emodin was increased in compared with the cells
not treated with emodin (Figure 2B). After 14 days of
differentiation and treatment, this increase was higher
when the concentration of emodin was 10 μM in the
gene studied, and this great increase continued for
21 days. The expression of transcription factors Runx2
and osterix were influenced positively. The expression of
Table 3 Effect of emodin on trabecular bone microarchitecture
BMD BV/TV Tb.N (1/mm) Tb.Th (mm) Tb.Sp (mm) Conn.D (1/mm3)
Sham 2.93 ± 0.07 0.25 ± 0.02 3.75 ± 0.13 0.12 ± 0.03 0.31 ± 0.06 115 ± 3.28
OVX 1.57 ± 0.11* 0.15 ± 0.02* 2.42 ± 0.16* 0.06 ± 0.02* 0.54 ± 0.08* 76 ± 2.32*
Emodin 2.85 ± 0.06** 0.22 ± 0.01** 3.28 ± 0.18** 0.09 ± 0.02 0.41 ± 0.05** 96 ± 2.76**
Data are presented as mean ± SEM (n = 8) *significantly different from the sham group:P < 0.05. **significantly different from OVX group: P < 0.05.
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induced but nontreated cells after 21 days (Figure 2C).
But the increase of osterix expression was only shown
after 21 days of treatment (Figure 2D). In addition, the
presence of emodin in the OM produced an increase in
the expression of the ALP gene (Figure 2E), especially, at
the concentration of 0.1 μM in 7 days.
Moreover, the expression of genes involved in the for-
mation of the cellular matrix was also increased by the
presence of emodin. On the seventh day of treatment, the
levels of expression for collagen type I were higher when
the concentrations were 1 μM or 10 μM (Figure 2F). After
14 days, a significant increase in collagen expression was
observed at a concentration of 10 μM and in osteocalcin
expression at 1 μM of emodin (Figure 2G). In addition,
emodin significantly increased Runx2 protein expression
by western blot analysis (Figure 2H).
The influence of emodin on the development of the
osteoblast phenotype from MSCs was evaluated by mon-
itoring the formation. When emodin was added to the
OM medium, the phosphatase alkaline staining showed
an increase in comparison with cells not treated with
emodin (Figure 2I, J, K, L).
Emodin down-regulates mRNA and protein expression of
adipogenesis markers
The expression of three marker genes for adipogenesis—the
transcription factor peroxisome proliferator-activated recep-
tor gamma (PPARγ), C/EBPα and the fatty acid-binding pro-
tein (ap2) gene—was studied in order to analyze the effect
of emodin on the differentiation of MSCs into adipocytes.
The expression of PPARγ was inhibited at the first mo-
ment of differentiation and treatment with the three con-
centrations of emodin. The rate of inhibition was inversely
proportional to the emodin concentration, and maximum
inhibition across the three concentrations was seen at
21 days (Figure 3A). The C/EBPα expression was inhibited
by emodin (Figure 3B); however, in the case of 10− 4 M, this
inhibition was not observed until 14 days of differentiation
and treatment. Moreover, the ap2 expression was also inhib-
ited in other cellular cultures differentiated with AM plus
emodin (Figure 3C). Emodin significantly decreased PPARγ
protein expression by western blot analysis (Figure 3D).
In addition, the influence of emodin on the adipocyte
phenotype was evaluated. The formation of lipid drop-
lets, a characteristic of the adipocyte formation process,was monitored using the oil red O staining. There were
major changes in the phenotype of differentiating MSCs
in the treated cells, mainly a decrease in the develop-
ment and accumulation of fat in the cells. So, the area
occupied by the lipid droplets was reduced at the three
concentrations of emodin and at all the time points, dif-
ferentiations were analyzed (Figure 3E). Aside from this,
there was no difference in fat accumulation due to the
concentration of emodin. And the size of the fat particles
was smaller compared with nontreated cells at 21 days of
differentiation and treatment (Figure 3F, G, H, I).
Discussion
It has been proposed that the close relationship between
increased adipocytes and decreased bone formation in con-
ditions of bone loss like age-related osteoporosis [13,14].
There are some evidences for a reciprocal relationship
between these cell lineages [15,16].
It has been suggested that targeting regulatory factors
that alter mesenchymal cell fate to increase the number of
osteoblasts and decrease adipocytes have the potential to
provide novel therapeutic approaches for osteoporosis.
This study provides the evidence for the therapy of
herbs containing emodin for osteoporosis, and reveals
the effect of emodin on enhancing osteogenesis and
inhibiting adipogenesis in vitro and in vivo. The emodin
prevents bone loss by modulating the differentiation of
the osteogenic and adipogenic lineages, as shown in the
enhancement of the osteogenic gene expression markers
and osteoblast phenotypic characteristics, eventually
promoting osteoblastogenesis. We hypothesize that emo-
din might protect the bone from bone volume loss by
enhancing osteogenesis and inhibiting adipogenesis dif-
ferentiation of BMSC. This prompted us to determine
the histomorphometric parameters of trabecular bone
after treating OVX-induced osteoporotic mice with emo-
din. It proved osteoblast number of emodin-OVX group
was higher than OVX group.
The values of trabecular bone volume, trabecular num-
ber and connectivity density in the emodin-treated OVX
mice were higher than those determined in OVX mice.
The result of immunohistochemical staining suggests
that emodin increases the protein level of Runx2 and de-
creases that of PPARγ. This result suggests that emodin
exert a balance between bone formation and bone mar-
row fat at the tissue level.
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Figure 2 Emodin can stimulate cell proliferation. It stimulates osteogenesis differentiation of BMSC. When it (0.1-10 μM) was added to the
OM culture of BMSC for 7, 14, 21 days. Quantitative PCR (qPCR) assay was performed to examine the expression of osteogenesis-specific genes.
A) MTT assays showed that emodin have significant effects on cell growth at the concentrations used (0.1-10 μM), but there are inhibition at
100 μM after 3 days treatment in BMSC (p > 0.05, compared with the group without emodin). In addition, emodin at concentrations of 0-100 μM
are inhibition at 48 h. B) Emodin increased the mRNA expression of BMP4 in BMSC in a dose-dependent manner, with more pronounced effect at
the concentration of 10 μM. C) Treatment with emodin at the concentration of 10 μM also significantly increased the mRNA expression of Runx2 in
osteogenesis differentiation of BMSC for 14 days and 21 days. D) Emodin increased the osterix mRNA expression. E) Emodin dose-dependently
enhanced the alkaline phosphatase (ALP) activity in BMSC, especially at the concentration of 10 μM. F) Emodin dose-dependently enhanced
the ColI mRNA expression. G) Emodin increased OCmRNA expression at concentrations of 10 μM for 21 days. H) Western blotting analyses of
the protein abundance of Runx2. β-actin was used as an invariant control for equal loading. P < 0.05 vs OVX group. ALP staining (I, J, K and L)
also showed treatment with emodin at the concentrations of 0.1and 10 μM increased the ALP activity in BMSC compared with the group
without emodin.
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the anabolic action of emodin on bone formation and
inhibiting bone marrow fat, the present study assessed the
capacity of osteogenesis and adipogenesis differentiationof BMSCs. Runx2 is a master transcription factor regulat-
ing both embryonic bone development and postnatal
osteoblastic function [17]. Increments in Runx2
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Figure 3 Emodin inhibits adipogenesis differentiation of BMSC. It (0.1-10 μM) was added to the AM culture of BMSC for 7, 14, 21 days.
Quantitative PCR (qPCR) assay was performed to examine the expression of adipogenesis-specific genes after treatment with emodin. A) Emodin
decreased the expression of PPARγmRNA in BMSC in a dose-dependent manner, with more pronounced effect at the concentration of 10 μM.
B) Treatment with emodin at the concentration of 10 μM also significantly decreased the expression of C/EBPαmRNA in osteogenesis differentiation of
BMSC for 14 days and 21 days. C) Emodin dose-dependently enhanced the ap2 in adipogenesis differentiation of BMSC, especially at the concentration
of 10 μM. D) Western blotting analyses of the protein abundance of PPARγ. β-actin was used as an invariant control for equal loading. P < 0.05 vs OVX
group. E) The number of lipid droplets that was formed from the BMSCs of emodin-OVX was significantly lower than that formed from the BMSCs of
OVX. Data are presented as mean ± SEM. Data presented are three independent experiments with triplicates within each experiment. P < 0.05,
significantly different from the OVX group. Oil red O staining also showed treatment with emodin at the concentrations of 0.1 μM and 10 μM
inhibited the adipogenesis differentiation of BMSC. *p < 0.05, when compared with the group without emodin (F, G, H, I).
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Cbfa1 [19]. Both are involved in the cellular decision to
initiate differentiation into an osteoblast and play a critical
role in maintaining osteoblast-specific expression during
osteoblastgenesis [20]. Similarly, the important role of em-
odin in osteoblast differentiation is also supported by the
observation of higher levels of expression of other osteo-
blast markers, such as ALP gene expression and activity
or the type I collagen gene expression. On protein level,
emodin increase Runx2 protein expression. Our results
further demonstrate that emodin in the AM caused a de-
crease in adipocyte formation from MSCs. The expression
of the most important regulators of adipogenesis, the
PPARγ, was inhibited in mRNA and protein by emodin.
Moreover, the expression of the other adipogenic marker
genes, such as ap2 and C/EBPα, and the phenotypiccharacteristic of adipocytes, as fat accumulators, showed a
decrease when emodin was present.
Recent advances in the elucidation of the pathophysi-
ology of osteoporosis in the elderly indicate that the loss of
balance between osteoblastogenesis and adipogenesis in
bone marrow cell differentiation is a key mechanism of
osteoporosis in older adults [21]. Indeed, in ovariectomized
rats, bone fat increases in parallel with bone loss [22]. Adi-
pocyte differentiation is under the control of PPARs, mem-
bers of the nuclear receptor superfamily, in concert with
members of the C/EBP family of basic leucine zipper nu-
clear transcription factors [23]. Previous studies have dem-
onstrated the PPARγ ligands have the potential to inhibit
β-catenin signaling [24] and inhibit Runx2-mediate tran-
scription of osteogenesis-related genes [25]. Our find-
ings show that emodin reduces the expression of PPARγ,
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ation into osteoblast. When PPARγ gene up-regulats, the
Runx2 and osterix inhibits. Therefore, this upward regula-
tion of osteogenesis gene expression by emodin could be
the mechanism through which this anthraquinone deriva-
tive drives its osteogenesis differentiaton and inhibited adi-
pogenesis differentiation on MSC. In this way, emodin
may be an antagonizes of the potential actions of the ex-
ogenous ligands of PPARγ. In addition, in spite of the limi-
tations in this study, these data can explain in part that the
Chinese herbs containing emodin could contribute to de-
creasing the risk of developing osteoporosis.
Conclusion
Taken together, the present data demonstrated that em-
odin treatment exerted its anabolic effects on trabecular
bone in an ovariectomized mice model of osteopor-
osis by increasing bone formation and decreasing bone
marrow fat. These data in vitro suggest that the emodin
can regulates the balance of MSCs differentiation into
osteoblasts and adipocytes. Therefore, further studies
should be pursued to test this effect in clinical trials to
determine whether emodin could be used as a drug or
nutrient.
Abbreviations
MSCs: Mesenchymal stem cells; BMSC: Bone marrow mesenchymal stem
cells; BMD: Bone mineral density; OVX: Ovariectomized; Runx2: Runt-related
transcription factor 2; PPARγ: The peroxisome proliferator-activated receptor
gamma; C/EBPα: CCAAT- enhancer binding protein; ap2: Fatty acid binding
protein; AM: Adipocyte media; OM: Osteoblast media.
Competing interest
All authors have no conflicts of interest.
Authors’ contributions
FY contributed to the design of the study. PWY, YQH and ZML contributed
to the creation of the Manual of Procedures, implementation of the study
protocol and acquisition of data. FY drafted the manuscript, and all authors
provided critical revision and have approved the final manuscript.
Acknowledgements
This work was supported in part by the Program of Natural Science Foundation
of China (81102610 to FY), Chinese Medicine Bureau of Shaanxi Province
(13-JC014 to FY) and Shaanxi key science and technology innovation team
(2013KCT-26).
Received: 27 August 2013 Accepted: 11 February 2014
Published: 24 February 2014
References
1. Hartsock RJ, Smith EB, Petty CS: Normal variations with aging of the
amount of hematopoietic tissue in bone marrow from the anterior iliac
crest: a study made from 177 cases of sudden death examined by
necropsy. Am J Clin Pathol 1965, 43:326–331.
2. Meunier P, Aaron J, Edouard C, Vignon G: Osteoporosis and the
replacement of cell populations of the marrow by adipose tissue: a
quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971,
80:147–154.
3. Juan PR, Astudillo P, Ríos S, Seitz G, Pino AM: Adipogenesis and
osteoporosis. Rev Méd Chile 2009, 137:827–836.
4. Duque G: Bone and fat connection in aging bone. Curr Opin Rheumatol
2008, 20:429–434.5. Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, Shen JH, Leng Y:
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid de-
hydrogenase type 1 and ameliorates metabolic disorder in diet-induced
obese mice. Br J Pharmacol 2010, 161:113–126.
6. Matsuda H, Shimoda H, Morikawa T, Yoshikawa M: Phytoestrogens from
the roots of Polygonum cuspidatum (Polygonaceae): structure-
requirement of hydroxyanthraquinones for estrogenic activity. Bioorg
Med Chem Lett 2001, 11:1839–1842.
7. Ghosh S, Das Sarma M, Patra A, Hazra B: Anti-inflammatory and anticancer
compounds isolated from Ventilago madraspatana Gaertn., Rubia
cordifolia Linn. and Lantana camara Linn. J Pharm Pharmacol 2010,
62:1158–1166.
8. Dong MX, Jia Y, Zhang YB, Li CC, Geng YT, Zhou L, Li XY, Liu JC, Niu YC:
Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition
of hepatic stellate cells activation. World J Gastroenterol 2009,
15:4753–4762.
9. Hwang JK, Noh EM, Moon SJ, Kim JM, Kwon KB, Park BH, You YO, Hwang
BM, Kim HJ, Kim BS, Lee SJ, Kim JS, Lee YR: Emodin suppresses inflamm
-atory responses and joint destruction in collagen-induced
arthritic mice. Rheumatology 2013, 52(9):1583–1591.
10. Lee SU, Shin HK, Min YK, Kim SH: Emodin accelerates osteoblast
differentiation through phosphatidylinositol 3-kinase activation and
bone morphogenetic protein-2 gene expression. Int Immunopharmacol
2008, 8:741–747.
11. Zhang C, Teng L, Shi Y, Jin J, Xue Y, Shang K, Gu J: Effect of emodin on
proliferation and differentiation of 3 T3-L1 preadipocyte and FAS
activity. Chin Med J 2002, 115:1035–1038.
12. Yang YQ, Yang GS: Effect of emodin on proliferation and differentiation
of rat preadipocytes. Zhongguo Zhong Yao Za Zhi 2007, 32(5):424–427.
13. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC: Linkage of
decreased bone mass with impaired osteoblastogenesis in a murine
model of accelerated senescence. J Clin Invest 1996, 97:1732–1740.
14. Verma S, Rajaratnam JH, Denyon J, Hoyland JA, Byers RJ: Adipocytic
proportion of bone marrow is inversely related to bone formation in
osteoporosis. J Clin Pathol 2002, 55:693–698.
15. Rosen CJ, Bouxsein ML: Mechanisms of disease: is osteoporosis the
obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35–43.
16. Rodríguez JP, Montecinos L, Ríos S, Reyes P, Martínez J: Mesenchymal stem
cells from osteoporotic patients produce a type I collagen-deficient
extracellular matrix favoring the adipogenic differentiation. J Cell Biochem
2000, 79:557–565.
17. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M,
Karsety G: A Cbfa1-dependent genetic pathway controls bone formation
beyond embryonic development. Genes Dev 1999, 13:1025–1036.
18. Komori T: Regulation of bone development and maintenance by Runx2.
Front Biosci 2008, 13:898–903.
19. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR,
de Crombrugghe B: The novel zinc finger-containing transcription factor
osterix is required for osteoblast differentiation and bone formation. Cell
2002, 108:17–29.
20. Komori T: Requisite roles of Runx2 and Cbfb in skeletal development.
J Bone Miner Metab 2003, 21:193–197.
21. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic
and suppresses osteogenic programs in mesenchymal marrow stroma/stem
cells: the role of PPARgamma2 transcription factor and TGF-beta/BMP
signaling pathways. Aging Cell 2004, 3:379–389.
22. Martin RB, Zissimos SL: Relationships between marrow fat and bone
turnover in ovariectomized and intact rats. Bone 1991, 12:123–131.
23. Rosen ED, MacDougald OA: Adipocyte differentiation from the inside out.
Nat Rev Mol Cell Biol 2006, 7:885–896.
24. Lu D, Carson DA: Repression of β-catenin signaling by PPARγ ligands.
Eur J Pharmacol 2010, 636:198–202.
25. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS:
Activation of peroxisome proliferator-activated receptor-γ inhibits the
Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem
2003, 278:23270–23277.
doi:10.1186/1472-6882-14-74
Cite this article as: Yang et al.: Emodin enhances osteogenesis and
inhibits adipogenesis. BMC Complementary and Alternative Medicine
2014 14:74.
